NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Zai Lab Limited American Depositary Shares (ZLAB) Stock Analysis

Zai Lab Limited American Depositary Shares (ZLAB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ZLAB

$24.20

−$0.88 (−3.51%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ZLAB with… →

ZLAB Key Statistics

As of Oct 21, 2026
Trading
Open
$24.85
Previous Close
$25.08
Day's Range
24.12–25.50
52-Week Range
15.96–29.49
Volume
1.20M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.72
Valuation
Market Cap
$2.72B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.04
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.70
Financials (FY)
Revenue (FY)
$460.16M+15.33%
Net Income (FY)
−$175.54M
Profit marginThe share of revenue left as profit after all costs and taxes.
−41.86%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
112.27M
1-Year Return
−16.98%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
931.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ZLAB closed at $24.20, −16.98% over 1 year.

Zai Lab Limited American Depositary Shares (ZLAB) has a market capitalization of $2.72B.

In fiscal 2025, ZLAB reported revenue of $460.16M.

ZLAB Stock Return by Calendar Year

Zai Lab Limited American Depositary Shares (ZLAB) return since Sep 2017: what $10,000 became

1 year
$10,000 $8,302
−16.98%
5 years
$10,000 $2,427
−75.73%
Since Sep 2017
$10,000 $8,665
−13.35%

If you had invested $10,000 in Zai Lab Limited American Depositary Shares (ZLAB) at the close on September 20, 2017, the earliest close on record here, it would have been worth $8,665 at the close on October 21, 2026: −13.35% in total, −1.57% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+37.19%
2025−32.65%
2024−4.17%
2023−10.98%
2022−51.15%
2021−53.56%
2020+225.41%
2019+79.11%
2018+9.37%
2017 (partial year)−23.99%

As of October 21, 2026.

ZLAB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$460.16M−$175.54M−38.1%
2024$398.99M−$257.10M−64.4%
2023$266.72M−$334.62M−125.5%
2022$215.04M−$443.29M−206.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$460.16M$269.08M−$223.57M−$175.54M−38.1%
2024$398.99M$251.13M−$273.95M−$257.10M−64.4%
2023$266.72M$170.90M−$374.14M−$334.62M−125.5%
2022$215.04M$141.02M−$392.89M−$443.29M−206.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ZLAB Valuation vs Biotechnology Median

Median of 608 stocks
MetricZLABBiotechnology medianvs median
P/S ratio6.0413.3055% below
Profit margin−41.86%−38.31%3.6 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Zai Lab Limited American Depositary Shares (ZLAB) carries a market capitalisation of $2.72B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 1,784 employees.

Over the past 52 weeks the price has ranged from $15.96 to $29.49. The most recent close on file for ZLAB is $24.20, dated October 21, 2026. That is −$0.88 (−3.51%) against the previous close. The latest close sits 51.63% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $460.16M. That is +15.33% against the prior fiscal year, when revenue was $398.99M. The same year closed with a net loss of $175.54M. The reported profit margin is −41.86%. That is 3.6 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −1.7.

Across the 4 fiscal years on file, revenue moves from $215.04M in 2022 to $460.16M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 6.04 times revenue. On price-to-sales that is 54.56% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.72. Daily returns over the trailing 9 years annualize to a volatility of 67.67%. Over the trailing twelve months the total return is −16.98%. Measured over 5 years, that is −24.66% a year compounded.

Growth & Income

The record shows no dividend for ZLAB.

The strongest complete calendar year on file is 2020 at +225.41%; the weakest is 2021 at −53.56%. Of the 8 complete calendar years on file, 3 finished higher. So far in 2026 the total return is +37.19%.

Peer Comparison

Zai Lab Limited American Depositary Shares (ZLAB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Zai Lab Limited American Depositary Shares ZLAB $2.72B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Zai Lab Limited American Depositary Shares has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Zai Lab Limited American Depositary Shares

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Visit website →